Association between early-onset colorectal cancer outcomes and established prognostic factors: a nationwide population-based study
Abstract
Summary Background The incidence of early-onset colorectal cancer (eoCRC; <50 years) is rising. Previous studies suggested that eoCRC patients have poorer outcomes than older adults. Whether this reflects distinct tumor biology or differences in stage at diagnosis and treatment patterns remains unclear. We compared clinicopathological features, treatment, and survival of eoCRC with average-onset (ao) and older-onset (oo)CRC in a nationwide cohort. Methods Clinicopathological data of all patients diagnosed with colorectal adenocarcinoma in the Netherlands from 1 January 2016 through 31 December 2022 were retrieved from the Netherlands Cancer Registry (NCR). Patients were categorized as eoCRC, aoCRC (50–69 years), and ooCRC (≥70 years). Multivariable regression and matched analyses were performed to account for established prognostic factors and predictors of treatment response. Findings Among 80,551 patients with CRC, 3917 (5%) were eoCRC, 34,499 (43%) were aoCRC, and 42,135 (52%) were ooCRC. EoCRC patients more often presented with advanced disease (stage III or IV) and left-sided colon or rectal cancer. Five-year relative survival (RS) for eoCRC, aoCRC and ooCRC patients was 70%, 77%, and 69%, respectively (crude excess hazard ratio [EHR] for eoCRC vs. aoCRC 1·32 [95% CI 1·24–1·41]). In patients with mismatch repair proficient (pMMR) stage IV disease, eoCRC was associated with better RS than aoCRC (EHR 0·87 [95% CI 0·80–0·94]), concurrent with more intensive first-line systemic therapy. After matching for disease characteristics and treatment, RS was similar between eoCRC and aoCRC (EHR 1·02 [95% CI 0·91–1·14]), whereas ooCRC patients retained worse survival. Interpretation The poorer crude survival observed in eoCRC is largely associated with more advanced disease at diagnosis, rather than evidence of intrinsically distinct tumor biology. After accounting for established prognostic factors and factors predicting treatment response, survival of eoCRC and aoCRC patients is similar, challenging the notion that eoCRC constitutes a separate biological disease entity. Funding ZonMw, Dutch Research Council.